Ask AI
ProCE Banner Activity

Key Updates in the Treatment of Hormone Receptor–Positive Breast Cancer

Clinical Thought
Experts discuss key updates in hormone receptor–positive breast cancer, including recent data presented at ASCO 2022.

Released: July 18, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP, FASCO

Patricia and James Cayne Chair for Junior Faculty
Associate Attending, Breast Medicine and Early Drug Development Services
Section Head, Endocrine Therapy Research Program
Memorial Sloan Kettering Cancer Center
Associate Attending, Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP: consultant: AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, Sun Pharma, Taiho Oncology; researcher: ADC Therapeutics, AstraZeneca, Clovis Oncology, Debiopharm, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, Zymeworks.

Faculty Disclosure

Primary Author

Erica L. Mayer, MD, MPH, FASCO

Director, Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Internal Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH: consultant: AstraZeneca, Gilead Sciences, Lilly, Novartis.

Laura Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant: Novartis, Puma; researcher: Merck, Phillips.